Caffeine is a central nervous system stimulant that increases alertness by antagonizing adenosine receptors (A1 and A2A), thereby enhancing neuronal firing and downstream neurotransmitter release, including norepinephrine and dopamine. In adolescents and young adults, caffeine-containing energy drinks can produce dose-dependent adverse effects, and excessive exposure may reach a threshold consistent with caffeine toxicity. Clinically, caffeine toxicity is not a disease entity by itself; it is an acute toxidrome driven by pharmacologic overstimulation, with symptoms that can involve the gastrointestinal tract, cardiovascular system, skeletal muscle, and neuropsychiatric domains.
Energy drinks often contain high caffeine per serving (commonly around 80–200 mg per can/bottle, depending on the product), and some beverages are marketed as “low-calorie,” potentially reducing perceived dietary risk while still delivering substantial stimulant load. Adolescents may have lower body mass and variable sensitivity to stimulants, and they can consume multiple servings in a short time. Risk increases further when caffeine is co-ingested with other stimulants such as nicotine, certain cold/attention medications (e.g., sympathomimetic decongestants or ADHD stimulants), or through energy-drink mixing with alcohol, which can mask intoxication while permitting ongoing stimulant intake.
The pathophysiology of caffeine toxicity involves competitive adenosine receptor blockade leading to increased catecholaminergic tone, plus effects on calcium handling and cyclic AMP pathways in excitable tissues. At higher doses, the sympathetic activation can precipitate tachycardia, hypertension, tremor, and agitation. Neurologically, patients may experience insomnia, restlessness, anxiety-like symptoms, and in severe cases, confusion, seizures, or delirium. Cardiovascular manifestations are especially important because caffeine’s sympathomimetic effects can increase myocardial oxygen demand and predispose susceptible individuals to arrhythmias.
Typical clinical features include nausea, vomiting, abdominal pain, dizziness, and diaphoresis. The cardiovascular profile may show sinus tachycardia as a common first sign; more serious rhythm disturbances, though less common, have been reported in overdose scenarios. Neuromuscular findings—such as muscle twitching or tremor—reflect generalized cortical and peripheral excitability. Psychiatric and behavioral effects can range from jitteriness to marked panic, irritability, and impaired judgment. In children and adolescents, clinicians must distinguish these symptoms from primary anxiety disorders, intoxication with other substances, and medication side effects.
Dose considerations are central to risk assessment. Toxicity correlates with mg/kg intake; while thresholds vary across individuals, adverse effects can begin with relatively modest doses in sensitive populations, and severe toxicity is more likely at higher mg/kg levels or with rapid ingestion of multiple servings. Because label timing and serving size confusion are common, clinicians should obtain a precise history of how many cans were consumed, over what timeframe, and whether any other stimulants were taken.
Evaluation in an acute setting focuses on stabilization and identification of complications. Vital signs, continuous cardiac monitoring, and neurologic assessment are recommended. Laboratory testing may include electrolytes, glucose, and, depending on severity, renal function and a targeted toxicology evaluation. Electrocardiography helps assess rhythm, QRS/QT intervals, and tachyarrhythmias. Treatment is primarily supportive: airway protection if needed, control of agitation (often with benzodiazepines), correction of dehydration and electrolyte abnormalities, and management of persistent tachyarrhythmias in consultation with toxicology or cardiology.
Decontamination is considered selectively. If presentation is early and ingestion is potentially life-threatening, activated charcoal may be appropriate, but it should be weighed against aspiration risk and the time elapsed since ingestion. Gastric lavage is rarely used and reserved for exceptional circumstances. Hemodynamic support follows standard critical care principles. Seizures, if present, are typically treated with benzodiazepines. In most cases of mild to moderate toxicity, symptoms resolve with time and supportive care, though monitoring is necessary because symptoms can evolve as absorption completes.
Prevention is the most effective strategy. Public health guidance generally emphasizes avoiding energy drinks in children and adolescents due to unpredictable dosing, marketing that targets youth, and vulnerability to rapid overconsumption. Clinicians and caregivers should encourage label literacy, discouraging mixing with other stimulants, and establishing caffeine ceilings individualized to age and comorbidities. For adolescents with anxiety disorders, sleep disorders, or cardiac conditions (including congenital arrhythmia syndromes), even typical caffeine doses may worsen symptoms.
From a clinical communication perspective, it is essential not to frame caffeine effects solely as “behavioral.” Although energy drinks can provoke anxiety-like symptoms, the underlying mechanism is pharmacologic stimulation with potential for physiologic harm. Therefore, clinicians should screen for stimulant use when evaluating acute anxiety, palpitations, tremor, or sleep disruption, and provide clear counseling on safer alternatives and limits.
Source: Breanna Morello (via X)
Breanna Morello: 🚨MAHA ALERT🚨 TX AG Ken Paxton has LAUNCHED an INVESTIGATION into the Celsius Energy Drink Company to protect Texas children from dangerous levels of caffeine. Alani Nu is a popular low-calorie caffeine energy drink that is marketed toward young adults. Each 12-ounce can. #breaking
— @BreannaMorello May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
